Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

ASCO 2025 | High survival rates in the SIENDO trial for endometrial cancer

Jalid Sehouli • 30 May 2025

ASCO 2025

Endometrial Cancer Gynecological Cancer

Jalid Sehouli, MD, Charité Universitätsmedizin Berlin, Berlin, Germany, discusses key findings of a post-hoc analysis of selinexor maintenance therapy in patients with advanced or recurrent TP53wt endometrial cancer. Results from the ENGOT-EN5/GOG-3055/SIENDO trial (NCT03555422) support selinexor’s high treatment efficacy as shown by progression free survival data independent of endometrial cancer subtypes, such as microsatellite instability status. This interview took place during the 2025 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.